Abstract:Background Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes might improve beta-cell function and result in extended glycaemic remissions. We did a multicentre, randomised trial to compare the effects of transient intensive insulin therapy (continuous subcutaneous insulin infusion [CSII] or multiple daily insulin injections [MDI]) with oral hypoglycaemic agents on beta-cell function and diabetes remission rate.Methods 382 patients, aged 25-70 years, were enrolled from nine centres in China between September, 2004, and October, 2006. The patients, with fasting plasma glucose of 7.0-16.7 mmol/L, were randomly assigned to therapy with insulin (CSII or MDI) or oral hypoglycaemic agents for initial rapid correction of hyperglycaemia. Treatment was stopped after normoglycaemia was maintained for 2 weeks. Patients were then followed-up on diet and exercise alone. Intravenous glucose tolerance tests were done and blood glucose, insulin, and proinsulin were measured before and after therapy withdrawal and at 1-year follow-up. Primary endpoint was time of glycaemic remission and remission rate at 1 year after short-term intensive therapy. Analysis was per protocol. This study was registered with ClinicalTrials.gov, number NCT00147836.Findings More patients achieved target glycaemic control in the insulin groups (97.1% [133 of 137] in CSII and 95.2% [118 of 124] in MDI) in less time (4. 0 days [SD 2.51 in CSII and 5.6 days [SD 3.8] in MDI) than those treated with oral hypoglycaemic agents (83.5% [101 of 1211 and 9.3 days [SD 5.31). Remission rates after 1 year were significantly higher in the insulin groups (51. 1% in CSII and 44.9% in MDI) than in the oral hypoglycaemic agents group (26.7%; p=0.0012). beta-cell function represented by HOMA B and acute insulin response improved significantly after intensive interventions. The increase in acute insulin response was sustained in the insulin groups but significantly declined in the oral hypoglycaemic agents group at 1 year in all patients in the remission group.Interpretation Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaernic agents.Funding 973 Programme from the Chinese Government, the Natural Science Foundation of Guangdong Province Government, Novo Nordisk (China), and Roche Diagnostics (Shanghai).

Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients is Associated with Improvement of Beta-Cell Function.

Remission of Hyperglycemia Following Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetic Patients: a Long-Term Follow-Up Study.

Predictors Of Long-Term Glycemic Remission After 2-Week Intensive Insulin Treatment In Newly Diagnosed Type 2 Diabetes

[Influencing Factors for the Curative Effects of Short-Term Continuous Subcutaneous Insulin Infusion on Newly Diagnosed Type 2 Diabetes].

Attitudes Toward Diabetes Affect Maintenance of Drug-Free Remission in Patients with Newly Diagnosed Type 2 Diabetes after Short-Term Continuous Subcutaneous Insulin Infusion Treatment

Induction of Long-Term Good Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment

Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

[The Effects of Early Intensive Therapy on Islet Beta Cell Function and Long-Term Glycemia Control in Newly Diagnosed Type 2 Diabetic Patients with Different Fasting Plasma Glucose Levels.].

Diabetes remission in newly diagnosed type 2 diabetes mellitus through short‐term continuous subcutaneous insulin infusion intensive therapy combined with low‐carbohydrate diet treatment

Short-term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and Β-Cell Function in Subjects with Long-Term Remission.

[The Effect and Mechanism of Transient Continuous Subcutaneous Insulin Infusion Therapy on Beta Cell Function, Insulin Resistance and Vascular Endothelial Injury in Newly Diagnosed Type 2 Diabetes].

Short-Term Continuous Subcutaneous Insulin Infusion Combined with Insulin Sensitizers Rosiglitazone, Metformin, or Antioxidant Α-Lipoic Acid in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Lower Mean Blood Glucose During Short‐term Intensive Insulin Therapy is Associated with Long‐term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes: Evidence‐based Recommendations for Standardization

1032-P: Time-in-Range during Short-Term Intensive Insulin Therapy Is Associated with Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes

A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity

Improvement of Β-Cell Function Ameliorated Glycemic Variability in Patients with Newly Diagnosed Type 2 Diabetes after Short-Term Continuous Subcutaneous Insulin Infusion or in Combination with Sitagliptin Treatment: a Randomized Control Trial

Effect of short-term intensive insulin therapy on α-cell function in patients with newly diagnosed type 2 diabetes.

A Randomized Trial of Insulin Glargine Plus Oral Hypoglycemic Agents Versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Effects of Short-Term Continuous Subcutaneous Insulin Infusion on Fasting Plasma Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus